Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00072514 · OUTCOME

Hematologic and Non-hematologic Adverse Events.

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies · Source last updated 2017-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
3-4 weeks after completion of study treatment

What was measured

Count of participants with grade 3/4 hematologic and non-hematologic adverse events.

Groups in this outcome

Treatment

Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment51

Reported measurements

Hematologic Grade 3
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment10Not reportedNot reportedNot reportedNot reported
Hematologic Grade 4
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment39Not reportedNot reportedNot reportedNot reported
Non-Hematologic Grade 3
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment23Not reportedNot reportedNot reportedNot reported
Non-Hematologic Grade 4
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        10
    title
    Hematologic Grade 3
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        39
    title
    Hematologic Grade 4
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        23
    title
    Non-Hematologic Grade 3
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Non-Hematologic Grade 4
denoms
  1. counts
    1. group Id
      OG000
      value
      51
    units
    Participants
description
Count of participants with grade 3/4 hematologic and non-hematologic adverse events.
groups
  1. description
    Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.
    id
    OG000
    title
    Treatment
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
3-4 weeks after completion of study treatment
title
Hematologic and Non-hematologic Adverse Events.
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice